JSMC
SCNI

Jess S. Morgan & Co’s Scinai Immunotherapeutics SCNI Stock Holding History

Jess S. Morgan & Co’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-745
Closed -$2.91M – 41
2020
Q3 		$2.91M Buy
745
+42
+6% +$161K 2.9% 14
2020
Q2 		$1.6M Buy
+703
New +$1.13M 1.74% 33

Other funds holding SCNI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM

Jess S. Morgan & Co's SCNI Position: Q4 2020 in Review

Jess S. Morgan & Co sold out of Scinai Immunotherapeutics (SCNI) in Q4 2020, closing a stake of 745 shares — an estimated $2.91M sold.

Jess S. Morgan & Co first reported a position in SCNI in Q2 2020 and held it in 2 quarters. The position peaked at $2.91M in Q3 2020. 13 funds tracked by Wall St. Rank hold SCNI as of Q4 2020.

  • Jess S. Morgan & Co reported no remaining Scinai Immunotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Jess S. Morgan & Co sold 745 Scinai Immunotherapeutics shares in Q4 2020, an estimated $2.91M.
  • Jess S. Morgan & Co first reported a position in Scinai Immunotherapeutics in Q2 2020 and held it in 2 quarters.
  • Jess S. Morgan & Co's Scinai Immunotherapeutics position peaked at $2.91M in Q3 2020.
  • 13 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2020.

Based on Jess S. Morgan & Co's 13F filing for Q4 2020, filed 30 Nov 2021.